Kageshita T - Search Results

1

Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.

Fukushima S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Ikuta Y, Ikeda T, Kageshita T, Ihn H, Nishimura Y, Senju S. Fukushima S, et al. Among authors: kageshita t. J Immunother. 2009 Apr;32(3):219-31. doi: 10.1097/CJI.0b013e318194b63b. J Immunother. 2009. PMID: 19242378

2

Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels.

Ikuta Y, Nakatsura T, Kageshita T, Fukushima S, Ito S, Wakamatsu K, Baba H, Nishimura Y. Ikuta Y, et al. Among authors: kageshita t. Clin Cancer Res. 2005 Nov 15;11(22):8079-88. doi: 10.1158/1078-0432.CCR-05-1074. Clin Cancer Res. 2005. PMID: 16299239

3

Differential expression of heat shock protein 105 in melanoma and melanocytic naevi.

Muchemwa FC, Nakatsura T, Fukushima S, Nishimura Y, Kageshita T, Ihn H. Muchemwa FC, et al. Among authors: kageshita t. Melanoma Res. 2008 Jun;18(3):166-71. doi: 10.1097/CMR.0b013e3282fe9a16. Melanoma Res. 2008. PMID: 18477890

4

Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses.

Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Monji M, et al. Among authors: kageshita t. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6047-57. doi: 10.1158/1078-0432.CCR-04-0475. Clin Cancer Res. 2004. PMID: 15447989

5

Identification of glypican-3 as a novel tumor marker for melanoma.

Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Nakatsura T, et al. Among authors: kageshita t. Clin Cancer Res. 2004 Oct 1;10(19):6612-21. doi: 10.1158/1078-0432.CCR-04-0348. Clin Cancer Res. 2004. PMID: 15475451

6

Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.

Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H. Yoshino Y, et al. Among authors: kageshita t. J Dermatol. 2008 Apr;35(4):206-14. doi: 10.1111/j.1346-8138.2008.00446.x. J Dermatol. 2008. PMID: 18419677

7

The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma.

Nishi H, Inoue Y, Kageshita T, Takata M, Ihn H. Nishi H, et al. Among authors: kageshita t. Biosci Trends. 2010 Apr;4(2):86-9. Biosci Trends. 2010. PMID: 20448346 Free article.

8

The prevalence of melanocytic nevi on the soles in the Japanese population.

Kogushi-Nishi H, Kawasaki J, Kageshita T, Ishihara T, Ihn H. Kogushi-Nishi H, et al. Among authors: kageshita t. J Am Acad Dermatol. 2009 May;60(5):767-71. doi: 10.1016/j.jaad.2008.12.048. J Am Acad Dermatol. 2009. PMID: 19389519

9

Amelanotic malignant melanoma where primary lesion was discovered 5 years after metastasis in the lymph node.

Kato H, Inoue Y, Ishihara T, Kageshita T, Ihn H. Kato H, et al. Among authors: kageshita t. J Dermatol. 2010 Aug;37(8):730-4. doi: 10.1111/j.1346-8138.2010.00909.x. J Dermatol. 2010. PMID: 20649717

10

Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell carcinoma.

Muchemwa FC, Nakatsura T, Ihn H, Kageshita T. Muchemwa FC, et al. Among authors: kageshita t. Br J Dermatol. 2006 Sep;155(3):582-5. doi: 10.1111/j.1365-2133.2006.07362.x. Br J Dermatol. 2006. PMID: 16911285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters